Join
Live feed
·
PRReleasevia Quantisnow
Agios Pharmaceuticals Inc. logo

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

ByQuantisnow·Wall Street's wire, on your screen.
AGIO· Agios Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGIO (Agios Pharmaceuticals Inc.) and more on Quantisnow.